Thera-SAbDab

BRIAKINUMAB

>   Structural Summary
TherapeuticBriakinumab
TargetIL12B
Heavy ChainQVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAFIRYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCKTHGSHDNWGQGTMVTVSS
Light ChainQSVLTQPPSVSGAPGQRVTISCSGSRSNIGSNTVKWYQQLPGTAPKLLIYYNDQRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDRYTHPALLFGTGTKVTVL
100% seqID Fv Structure5n2k [Fvs: BA, DC, FE, LK, NM, PO], 5njd [Fvs: NM, PO, RQ, TS, VU, XW]
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (October '21)Preregistration (w)
Estimated Status (October '21)Discontinued
Recorded Developmental Technologyna
INN Year Proposed2009
INN Year Recommended2010
Companies InvolvedCambridge Antibody Technology, Abbott GmbH & Co. KG
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedPlaque psoriasis, Crohn's disease, Multiple sclerosis, Rheumatoid arthritis
Notes

SAbDab papers

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

Dunbar, J., Krawczyk, K. et al. (2014) SAbDab: the Structural Antibody Database. Nucleic Acids Res. 42(D1):D1140-D1146 [link]

Thera-SAbDab paper

Raybould, M.I.J., Marks, C. et al (2020) Thera-SAbDab: the Therapeutic Structural Antibody Database. Nucleic Acids Res. 48(D1):D383-D388. [link]

Our privacy policy